Noopur Raje

Sep 2, 2024 | cancernetwork.com | Rahul Banerjee |Noopur Raje

In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy.

Jan 30, 2024 | onclive.com | Rafat Abonour |Noopur Raje

Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.

Jan 30, 2024 | onclive.com | Rafat Abonour |Noopur Raje

Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.

Jan 23, 2024 | onclive.com | Rafat Abonour |Noopur Raje

KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MMExperts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.

Jan 23, 2024 | onclive.com | Rafat Abonour |Noopur Raje

CIBMTR Registry and CARTITUDE-2: Trial of Cilta-Cel in Patients with MMDr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).